Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi), a biological pathway for selectively silencing genes. The company has no commercial manufacturing capabilities and relies on strategic alliances and government contracts for funding. Its lead program, ALN-RSV01 for respiratory syncytial virus (RSV), was in Phase I clinical trials. Other programs include pandemic flu (with Novartis), hypercholesterolemia, and various discovery programs for CNS diseases and viral infections.
Key Financial Metrics
| Metric (in thousands) | 2006 | 2005 |
|---|---|---|
| Net Revenues | $26,930 | $5,716 |
| Operating Expenses | $66,431 | $49,188 |
| Research & Development | $49,798 | $35,319 |
| General & Administrative | $16,633 | $13,869 |
| Loss from Operations | $(39,501) | $(43,472) |
| Net Loss | $(34,608) | $(42,914) |
| Cash, Cash Equivalents & Marketable Securities | $217,260 | $80,002 |
| Working Capital | $199,859 | $63,930 |
| Total Debt (Notes Payable) | $9,136 | $7,395 |
| Accumulated Deficit | $(140,527) | $(105,919) |
Note: The company reported a net loss per share of $(1.09) for 2006 compared to $(1.96) for 2005.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 371% to $26.9 million, driven primarily by the Novartis collaboration (which accounted for $21.8 million in 2006 vs. $0.7 million in 2005) and the initiation of the Novartis pandemic flu alliance.
- Expense Increase: Operating expenses rose 35% to $66.4 million. R&D expenses increased 41% to $49.8 million, largely due to clinical trial and manufacturing costs for the RSV program and increased headcount.
- Liquidity Improvement: Cash and marketable securities more than doubled to $217.3 million, fueled by $163.3 million in net proceeds from public stock offerings in January and December 2006.
- Stock-Based Compensation: Adoption of SFAS 123R in 2006 resulted in a significant increase in recognized stock-based compensation expense ($8.3 million in 2006 vs. $4.6 million in 2005).
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant losses as it advances clinical trials and expands its pipeline. Future funding is expected to come from equity offerings, collaboration milestones, and government contracts. The company believes its current resources are sufficient to fund operations for at least the next several years.
Key Risks and Contingencies:
- Technology Risk: RNAi is an unproven therapeutic platform; no RNAi drugs have received regulatory approval. Challenges include delivery, stability, and potential off-target effects.
- Dependence on Collaborators: The company relies heavily on Novartis (which owns ~14% of stock) and Merck for funding and commercialization. Termination of these agreements would severely impact operations.
- Intellectual Property: The company faces potential patent litigation and oppositions (e.g., regarding the Kreutzer-Limmer patents) which could invalidate key IP rights.
- Regulatory Approval: Success in early clinical trials does not guarantee approval. The FDA has not established definitive policies for RNAi drugs.
- Government Funding: A $23 million contract with the NIH for Ebola virus research is subject to future budgetary appropriations.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $217 million cash balance against the projected $49.8 million annual R&D spend and increasing operating costs.
- Novartis Agreement Terms: Review the specific milestones and revenue recognition policies for the Novartis collaboration, which drives the majority of current revenue.
- Patent Status: Monitor the status of opposition proceedings against the Kreutzer-Limmer patents (EP 1144623 and EP 1214945) and the Tuschl II patents.
- Clinical Trial Progress: Track the safety and efficacy data from the Phase I trials for ALN-RSV01 and the initiation of trials for the pandemic flu program.
- Stock Dilution: Assess the impact of future equity financings required to fund operations, noting Novartis's right to maintain its ownership percentage.